Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 02:07 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
A Phase 2 Trial to Evaluate if Corifollitropin Alfa (Org 36286), Followed by a Low Daily Dose of hCG or Recombinant FSH Can Induce Monofollicular Growth in Women With WHO Group II Anovulatory Infertility (P05693)
NCT00697255 · Organon and Co · PHASE2 · terminated · last registry update 2024-06-17 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
No reason was published
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | The registry record gives no reason | – | Registry record, Organon and Co |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against FSHR within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2025-05-18Results posted on the registry: Instituto Bernabeu, Corifollitropin Alfa + Follitropin Alfa (NCT05815719)
- 2025-04-02Results posted on the registry: Ferring Pharmaceuticals, REKOVELLE (Follitropin Delta) (NCT05263388)
- 2025-01-28Also stopped (terminated): CRG UZ Brussel, Estradiol Valerate + Micronized progesterone (NCT03976544)
- 2024-12-13Results posted on the registry: Peter Kovacs MD, Follitropin Alfa + Follitropin delta (NCT05103228)
- 2024-08-20Phase 3 first posted: Changchun GeneScience Pharmaceutical Co., Ltd., recombinant human follicle-stimulating hormone-CTP Fusion protein injection + recombinant human follicle-stimulating hormone-CTP Fusion protein injection Placebo (NCT06561594)
- 2024-07-05Phase 3 first posted: Cairo University, Gonadotropin + Letrozole (NCT06486870)
- 2024-05-22Also stopped (terminated): Fundacion Dexeus, Testosterone gel + Placebo gel (NCT02418572)
- 2024-05-17Phase 3 first posted: Ain Shams University, Alpha lipoic acid + Letrozole (NCT06418347)
- 2024-05-13Results posted on the registry: Ferring Pharmaceuticals, FE 999049 + GnRH agonist (GONAPEPTYL) + FE 999049 + GnRH antagonist (CETROTIDE) (NCT03809429)
- 2024-02-28Also stopped (withdrawn): CRG UZ Brussel, Lutropin alfa + Follitropin alfa (NCT05405686)
- 2024-01-29Phase 3 first posted: Ellen Greenblatt, Luveris (NCT06227949)
- 2024-01-26Also stopped (withdrawn): Clínica EUGIN, a drug against FSHR (NCT05948293)
- 2024-01-18Results posted on the registry: Ferring Pharmaceuticals, Follitropin delta (NCT03740737)
- 2024-01-18Results posted on the registry: Ferring Pharmaceuticals, Follitropin delta + Placebo (NCT03738618)
- 2024-01-10Phase 3 first posted: Royan Institute, a drug against FSHR (NCT06199960)
- 2023-12-18Phase 3 first posted: Ferring Pharmaceuticals, FE 999049 + GONAL-F (NCT06173869)
- 2023-11-18Phase 3 first posted: Fundación Santiago Dexeus Font, 150μg CFA (Elonva®) at stimulation day (SD) 1 and 100μg CFA(Elonva®) at SD 5 + 150μg CFA (Elonva®) at SD 1 following by rFSH (Puregon®) 200IU daily from SD 8 until the day of the trigger (NCT06134479)
- 2023-11-07Results posted on the registry: Ferring Pharmaceuticals, MENOPUR solution for injection in pre-filled pen, 1200 IU/1.92 mL + MENOPUR powder and solvent for solution for injection, 75 IU (NCT04163458)
- 2023-10-19Phase 3 first posted: Changchun GeneScience Pharmaceutical Co., Ltd., GenSci094 + Placebo RecFSH / follitropin alfa (NCT06091436)
- 2023-09-21Phase 3 first posted: Beni-Suef University, Intra ovarian by platelet rich plasma (NCT06048666)
- 2023-08-24Also stopped (terminated): Institut Curie, a drug against FSHR (NCT02860481)
- 2023-07-20Also stopped (withdrawn): AGUNCO Obstetrics and Gynecology Centre, Recombinant FSH (rFSH) (NCT01267604)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision